7 completed, 2 withdrawn. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Withdrawn 2 |
| Phase 2 | 3 | Completed 3 |
Follow EuroVacc Foundation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L, DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above), DNA-HIV-PT123 4mg and CN54gp140/MPLA-L - Healthy Adults | Phase 1 | Completed | ANRS, Emerging Infectious Diseases | 68 | 2022-08-05 | 2026-06-08 |
| A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02) Vaccine and vedolizumab (Entyvio), Placebo vaccine and vedolizumab infusion (Entyvio), Placebo vaccine and placebo infusion - HIV-1-infection | Phase 2 | Completed | ANRS, Emerging Infectious Diseases | 2 | 2022-06-21 | 2023-08-04 |
| A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48), Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48), Vaccine Group C: Saline placebo (weeks 0,4,24,48) - HIV Infections | Phase 2 | Completed | MRC/UVRI and LSHTM Uganda Research Unit | 1512 | 2020-12-15 | 2025-01-22 |
| Evaluation of the Effect of Late Boost on HIV-uninfected Vaccines From EV06 Trial DNA-HIV-PT123 & AIDSVAX B/E - HIV/AIDS | Phase 1 | Completed | EuroVacc Foundation | 49 | 2017-03-15 | 2019-02-07 |
| Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS DNA, AIDSVAX B/E - HIV/AIDS | Phase 1 | Completed | EuroVacc Foundation | 72 | 2014-09-01 | 2016-01-22 |
| Safety of and Immune Response to Prime/Boost Vaccine Regimens in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adults NYVAC-B, Placebo, rAd5 - HIV Infections | Phase 1 | Completed | HIV Vaccine Trials Network | 80 | 2009-08-01 | 2013-09-06 |
| Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers DNA-C, NYVAC-C - HIV Infections | Phase 1 / Phase 2 | Completed | ANRS, Emerging Infectious Diseases | 147 | 2007-07-01 | 2026-04-08 |
| Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa DNA-HIV-PT123 vaccine, NYVAC-HIV-PT1 vaccine, NYVAC-HIV-PT4 vaccine - HIV Infections | Phase 1 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-10-15 | ||
| Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults DNA-HIV-PT123, NYVAC-HIV-PT1, NYVAC-HIV-PT4 - HIV Infections | Phase 1 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-10-15 |
HIV Infections (5) · Acquired Immunodeficiency Syndrome (2) · Trematode Infections (1)
AIDSVAX B-E (3) · AIDSVAX (1) · DNA (1) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1) · NYVAC-C vaccine (1) · Vaccines (1) · emtricitabine tenofovir alafenamide (1) · vedolizumab (1)
Switzerland (4) · France (3) · Uganda (3) · United Kingdom (2)
Pontiano Kaleebu (2) · Giuseppe Pantaleo (1) · Jonathan Weber, PhD (1) · Magdalena Sobieszczyk (1) · Michael Keefer (1) · Pierre-Alexandre Bart, MD (1) · Pontiano Kaleebu, PhD (1) · Sheena McCormack, MSc (1) · Yves Levy, MD (1)
PMID 25271627, PMID 32589686, PMID 34843602, PMID 36357877, PMID 40268488, PMID 41259346, PMID 41650395, PMID 42141483, PMID 42410635
U01AI068614 (1)